Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Another R/S

<< Previous

Bullboard Posts

Next >>

Comment by Marky1on Apr 10, 2021 1:27pm

163 Views

Post# 32972876

RE:RE:RE:RE:RE:RE:RE:Another R/S

Just read your comment Mugsy...As usual, right on the money!! Slow, well planned, well thought of, Biden approach is where we are headed..
Again, I'll say it...Please hold on to your precious shares....look at the SP perhaps at the end of the day, or the week...No place for emotions here...I'm holding my 15,000 shares until we are bought out by some very astute Big Pharma...Bayer ( probably since we have our foot in the door, Dr.Hauts foot ). Or Pfizer...
Peace Out

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity